Introduction
============

Chronic obstructive pulmonary disease (COPD) is one of the most important respiratory problems we face today. It is the fourth leading cause of morbidity and mortality in the developed world ([@b22-copd-3-701]). In Spain, COPD affects 9.1% of the general population between 40 and 69 years of age ([@b29-copd-3-701]), and is responsible for approximately 10%--12% of primary care visits and 35%--40% of visits to a pneumologist. It also causes 35% of permanent work disabilities and 7% of hospital admissions ([@b22-copd-3-701]; [@b1-copd-3-701]). Because of the growing morbidity and mortality associated with this disease, it causes a high utilization of health care resources and a large economic burden to society. Thus, it has been reported that the expenses caused by this disease in Spain amount by 2% of the national health annual budget and 0.25% of the gross domestic product ([@b1-copd-3-701]). Furthermore, it is predicted that the impact of this disease will increase in coming years as a result of the rise in the life expectancy of the population, the increase in its prevalence and the emergence of new drugs and treatment modalities. Despite this, there are few studies in Spain that have quantified the costs of COPD ([@b11-copd-3-701]; [@b10-copd-3-701]; [@b20-copd-3-701]; [@b13-copd-3-701]; [@b14-copd-3-701]; [@b17-copd-3-701]; [@b25-copd-3-701]), and they differ in the criteria used for sampling and for assessment of the resources consumed. As a result, they also differ in the findings obtained. In addition, most of these studies had a small sample size and included patients from different care levels.

The primary objective of this study was to estimate the annual cost generated by patients with stable COPD followed in primary care facilities in Spain. The secondary objective was to analyze the possible variables with ability to predict the cost of the disease.

Materials and methods
=====================

Design and study population
---------------------------

This analysis is part of the EPIDEPOC study, a multicenter, epidemiological, observational, descriptive study carried out in the primary care setting to estimate the use of health care resources and to assess the quality of life of patients with stable COPD ([@b6-copd-3-701]). The recruitment of patients and calculation of sample size corresponded to that performed in the EPIDEPOC study ([@b6-copd-3-701]). For calculation of sample size, a cluster design was used, considering 3 types of variables: health centers, physicians, and medical records. As the health centers were considered to be homogeneous and representative of the Spanish geographical population, the medical record was chosen as the unit of study and the prescriber as the cluster. A previous study in a large cohort of 1,510 primary care patients found that the average annual cost per patient varied widely, with an estimated standard deviation of €3,407 ([@b13-copd-3-701]). Assuming a precision of €90, 5,505 medical records needed to be evaluated. If the effect of the cluster design is also taken into account, ie, the loss of efficacy from the use of clusters, assuming a correlation of 0.3 and a cluster size of 5, a total of 2,422 prescribers and 12,111 medical records would be required.

Patients were selected consecutively by primary care physicians from all Spanish autonomous communities, whose distribution was weighted based on the population of each community. Patients were recruited during a period of 3 months (from January 1 to March 31, 2003). Subjects of both sexes, aged 40 years or older, and diagnosed with COPD at least 12 months before the start of the study, were included. The diagnosis of COPD was performed according to the criteria of the Spanish Society of Pneumology and Chest Surgery (SEPAR) and was based on demonstration by means of forced spirometry of a forced expiratory volume in 1 second (FEV~1~) less than 80% of the predicted value and a FEV~1~/forced vital capacity (FVC) ratio less than 0.7 after the bronchodilation test. The severity of the disease was classified into three levels based on the FEV~1~ value: mild (FEV~1~ of 60%--80% of predicted value), moderate (FEV~1~ 40%--59% of predicted value) and severe (FEV~1~ less than 40% predicted value), in accordance with the SEPAR criteria ([@b5-copd-3-701]). Patients with a neurological or psychiatric illness that would preclude their assessment during the study were excluded. Patients with an acute exacerbation of COPD in the previous month were also excluded. An acute exacerbation was considered to be the occurrence of an impairment of the clinical condition of the patient characterized by increased baseline dyspnea, purulent sputum, increased volume of sputum or any combination of these symptoms.

The study was approved by the Ethics Committee of the Alcorcón Hospital Foundation, and all patients gave their oral consent to participate in it.

Assessment of patients
----------------------

A single visit was completed in which sociodemographic data, year of COPD diagnosis, severity of the disease, comorbidity, and utilization of health care resources in the previous 12 months was collected. All patients were administered the short form 12-item (SF-12) quality of life questionnaire, an abbreviated version of the SF-36 health questionnaire ([@b32-copd-3-701]). These 12 items explain more than 90% of the variance of the physical and mental component scores of the SF-36. The physical (PCS-12) and mental component summary (MCS-12) scores are then calculated, using a value of 50 with a standard deviation of 10 as the reference population. The SF-12 is scored from 0 to 100 with higher scores indicating better health status.

Direct costs were calculated from the information on the different procedures provided by the managements of Madrid Health Area 8 and the Alcorcón and Móstoles Hospitals. Indirect costs were calculated using the human capital method. This method is based on the assumption that the value of the lost production is equal to the wages associated with obtaining this production. In other words, a day missed from work implies a loss of production equal to the wages that would have been earned on that day. The information on employment and wages was obtained from the Spanish Statistical Office.

Statistical analysis
--------------------

Statistical analysis of the data was carried out using the SPSS 12.0 for Windows statistical package (SPSS Inc., Chicago, IL). Qualitative variables were described by frequency and percentage and quantitative variables by mean, standard deviation, minimum and maximum. The Pearson χ^2^ test was used to analyze the relationship between qualitative variables. Student's t test for independent measurements was used to calculate the differences in the means of the two groups and the ANOVA test to study the differences between more than two groups of patients. Finally, a multiple linear regression analysis was performed using the total annual cost per COPD patient as the dependent variable. Variables significant in the bivariate analysis or deemed clinically relevant were included in the model. All statistical tests were two-tailed and a value of p \< 0.05 was considered significant.

Results
=======

The number of physicians participating in the study was 2,377, which allowed a total of 10,711 patients (75.6% men) to be recruited, with a mean age of 67.1 ± 9.66 years. [Table 1](#t1-copd-3-701){ref-type="table"} show the sociodemographic and clinical characteristics of the sample studied. The mean FEV~1~ value was 57.4 ± 13.4%. The severity of the disease was mild in 35.5% of cases, moderate in 53.4% and severe in 11.2%. The most frequent observed comorbidities were hypertension (47.7%), hypercholesterolemia (41.3%), anxiety (22.2%), heart disease (18.8%), gastroduodenal ulcer (17.4%), diabetes (16.9%), and depression (12.8%). The mean PCS-12 and MCS-12 scores on the SF-12 quality of life questionnaire were 35.9 ± 10.3 and 48.2 ± 11.4, respectively. The mean number of drugs prescribed to the patients was 2.28 ± 1.03. The most frequently prescribed drugs were anti-cholinergics (84.8%), followed by short-acting β~2~-agonists (38.9%), inhaled corticoids (22.1%), theophyllines (11.8%), long-acting β~2~-agonists (9.5%), mucolytics (8.9%), and oral corticoids (4.6%).

With regard to the use of health care resources in the previous year, the mean values were: visits to primary care physicians; 6.66 ± 5.71, visits to pneumologists; 1.43 ± 1.52, visits to emergency rooms; 1.60 ± 2.71 and hospital admissions; 0.50 ± 1.17 ([Table 2](#t2-copd-3-701){ref-type="table"}). When the possible factors related to the use of health care resources were analyzed, a significant association was found with sex, with a significantly higher number of hospital admissions in men than in women (0.53 ± 1.24 versus 0.33 ± 0.93, p \< 0.001), although there were no differences in the number of visits to primary care or specialist physicians or in the duration of disability leaves. As expected, a statistically significant association was found between the use of health care resources and the age of the patients; the older the patient, the more frequent was the use of health care resources ([Table 3](#t3-copd-3-701){ref-type="table"}). Finally, a clear association was found between the use of health care resources and the severity of COPD: patients with a more severe disease consumed more health care resources in terms of the number of visits to primary care, pneumologist and emergency rooms, the number of hospital admissions and duration of work disability ([Table 4](#t4-copd-3-701){ref-type="table"}).

The total annual cost per COPD patient was €1,922.60 ± 2,306.44, with the largest component for hospital admissions (€788.72 ± 1,766.65), followed by cost of drugs (€492.87 ± 412.15) and cost of visits to emergency rooms (€134.32 ± 195.44, [Figure 1](#f1-copd-3-701){ref-type="fig"}). Significant higher total annual costs were found in men than in women ([Table 5](#t5-copd-3-701){ref-type="table"}), and in smokers and ex-smokers than in nonsmoker subjects ([Table 6](#t6-copd-3-701){ref-type="table"}). Age and severity of disease was also shown to be associated with total costs, with differences according to gender at different levels of age and severity of disease. In men, both factors were found to be independently significant without interaction. In women, only severity of COPD was found to be statistically significant ([Figure 2](#f2-copd-3-701){ref-type="fig"}). As expected, patients with hospital admissions showed higher total annual costs than subjects without admissions ([Table 7](#t7-copd-3-701){ref-type="table"}).

On the other hand, a significant association between total costs and quality of life, as assessed with SF-12 questionnaire, was found with physical and mental components of quality of life. Subjects with worse quality of life showed higher costs, independently of gender ([Figure 3](#f3-copd-3-701){ref-type="fig"}). This figure shows the impact of poorer quality of life on total costs by quartiles of physical and mental components according to sex: The mental component showed a significant interaction with sex.

Linear regression analysis found associated heart disease, FEV~1~, physical component of quality of life, number of medical visits (primary care physician, pneumologist and emergency room), hospital admissions (frequency and duration of stay) and duration of working disability to be significant predictors of the total annual cost ([Table 8](#t8-copd-3-701){ref-type="table"}).

Discussion
==========

This study showed that the total cost per COPD patient was near €2,000 per year when primary care physicians take care on these subjects. Concomitant heart disease, reduced FEV~1~, poor physical component of quality of life, increased number of medical visits, hospital admissions and incapacitating days for work were found to be explanatory variables associated with increased costs. The strength of this study lies in the elevated number of patients with stable COPD recruited in primary care clinics in Spain, including patients with multiple comorbidities, which are usually excluded from clinical trials. The study thus reflects real-world data. It should be taken into account that most Spanish patients with COPD are treated by general practitioners and that the proportion of patients referred to specialists is lower than in other West European countries (Esteban et al 2003).

Previous studies have shown health care total annual cost per COPD patient to vary between €1,100 and €3,400, with a median cost of about €2,000, a figure that is similar to that obtained in our study ([@b10-copd-3-701]; [@b13-copd-3-701]; [@b20-copd-3-701]; [@b14-copd-3-701]; [@b17-copd-3-701]). The distribution of costs found in this study also shows considerable agreement with data provided by other authors: approximately 40% of the cost is produced by the hospitalization component, which represents the largest proportion of the cost. Second most important component in term of cost was drug costs, which in our study represented almost 26% of the total expenses, being this value lower than that obtained in other studies. These differences might be explained by the greater severity of the patients included in our study. Thus, it has been shown an interaction between severity of disease and components of cost; as the severity of the disease increases, not only does the cost increase, but the distribution of costs changes as could be expected to some extend. Hence, hospital stay costs increase with severity of disease, and at the same time drug costs are reduced. In this way, a recent study carried out in our setting showed that drug therapy accounted for 43% of total direct costs in mild COPD, but that this percentage decreased to 37.6% and 28.4% in moderate and severe stages, respectively ([@b14-copd-3-701]).

The reduction of lung function in COPD patients is associated with a higher number of cardiovascular events and deaths from a cardiac cause, although the mechanisms responsible for this association are not well known. A relationship between COPD and cardiovascular diseases, linked to a systemic inflammatory component, has been observed even in patients with mild or moderate obstruction ([@b31-copd-3-701]). This study showed that the prevalence of heart disease associated with COPD was high (18.8%), and that it was one of the major determinants of the overall cost of the disease. These results contrast with those obtained in a recent study with a similar prevalence of cardiovascular events, in which no differences were observed in the annual cost per patient according to the presence or absence of these events ([@b25-copd-3-701]). The authors of this study noted that certain limitations of the study require caution when generalizing the results, such as the design of the study itself, possible variability between the different participating physicians and the coordination of care levels, which complicates measurement of cost-effective interventions. However, and whether or not is confirmed that a relationship exists between COPD and cardiovascular diseases, linked to the systemic inflammatory component present in these patients, not only would it lead to an important advance in knowledge of the disease, but would allow new treatment strategies to be designed that should act on various inflammatory mediators, with the aim of modifying the risk of developing complications and reducing mortality ([@b27-copd-3-701], [@b28-copd-3-701]; [@b4-copd-3-701]).

The cost of management of COPD also depends, as was seen in this study, on the severity of airflow obstruction measured by FEV~1~. Along this same line, [@b12-copd-3-701] showed that the severity of COPD was strongly correlated with health care resource utilization and consequently with the total cost of the disease. The average direct cost per patient per year over a 5-year follow-up was US\$1,681 in ATS stage I ([@b2-copd-3-701]), \$5,037 in stage II and \$10,812 in stage III. Subsequently, [@b17-copd-3-701] also found an increase in costs as the severity of the disease increased: the cost of severe COPD was 7 times that of mild COPD and 3 times that of moderate COPD. Despite the above, a more recent study showed that although airflow obstruction is a valid predictor of health care resource utilization, its influence is small, and that the presence of comorbid conditions and symptoms of dyspnea are better predictors of costs ([@b16-copd-3-701]).

Various authors have suggested the existence of other factors that may influence the cost of COPD ([@b18-copd-3-701]; [@b30-copd-3-701]). One of these is health-related quality of life, which could explain why some COPD patients have a high utilization of health care resources and generate a high demand for these resources, as pointed out by [@b30-copd-3-701]. Our study showed that the physical component of quality of life is one of the factors independently influencing the overall cost of COPD. Previous studies that assessed the health status of patients with this disease in Spain found a worse quality of life in those who had more dyspnea, a greater degree of obstruction, were treated with more drugs, suffered more exacerbations, and required more visits to emergency rooms and hospital admissions ([@b19-copd-3-701], [@b21-copd-3-701]; [@b23-copd-3-701]; [@b7-copd-3-701]; [@b6-copd-3-701].

Health care resource utilization is another of the major components of the cost of COPD, as shown in previous works ([@b16-copd-3-701]). In this study, it was observed that among the factors determining the cost of COPD were the number of visits to the primary care physicians, the pneumologists and emergency rooms, as well as the number of hospital admissions and their duration. Therefore, strategies for management of COPD should emphasize measures to control chronic symptoms and reduce exacerbations and hospitalizations, because the largest part of the cost of this disease is related to hospitalization. Furthermore, a previous study analyzing the costs of hospitalization found that the cost of the stay accounted for 70% of the total cost of care of the hospitalized COPD patient, whereas the cost of medical care, examinations or the drugs used was less than a third of the total ([@b24-copd-3-701]). In this context, optimization of resources does not lie in controlling the number of complementary examinations, but in reducing the number of days of hospital stay ([@b8-copd-3-701]).

The indirect costs of COPD are more difficult to assess. There are few articles in Spain that have assessed this component and the results obtained varied widely, which has made their interpretation difficult ([@b15-copd-3-701]; [@b13-copd-3-701]). It has been shown that patients with COPD have greater impairment of their ability to work and therefore are more likely to be disabled from work than those without this disease ([@b26-copd-3-701]). However, the estimated prevalence of work disability due to COPD remains controversial. Thus, [@b3-copd-3-701] indicated that asthma and COPD accounted for 3% of permanent work disabilities in Spain in the period 1999--2000, a figure that rose to 5.3% in the group of patients between 50 and 64 years of age. However, this figure is very far from that estimated by the Spanish Society of Pneumology and Chest Surgery (SEPAR), which indicated that 35% of permanent work disabilities are due to COPD ([@b1-copd-3-701]; [@b22-copd-3-701]). Regardless of the actual prevalence, this study found that the duration of disability leaves was a factor that contributed independently to increasing the cost of this disease.

There are some limitations in our study. We excluded subjects with serious neurological and psychiatric diseases, and patients with recent exacerbations of COPD. As these disorders are expected to be associated with higher utilization of health care resources, we can not exclude an underestimation of the real cost of COPD. In spite of these limitations, the data presented along with the predicted increase in the health care cost of COPD in the future, both in terms of its direct and indirect costs ([@b22-copd-3-701]), underscore the need for developing strategies aimed to optimize the use of resources devoted to the management of COPD, with special attention to early diagnosis.
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###### 

Sociodemographic and clinical characteristics of the patients studied

  Characteristic (no of patients)                                 
  --------------------------------------------------------------- ---------------------
  Total no of patients                                            10711
  Age (years)[\*](#tfn1-copd-3-701){ref-type="table-fn"} (8865)   64.1 ± 9.7 (40; 98)
  Age groups (8862)                                               
  40--54 years                                                    963 (10.9)
  55--64 years                                                    2249 (25.4)
  65--74 years                                                    3669 (41.4)
  \>75 years                                                      1981 (22.4)
  Sex (men) (10,620)                                              8030 (75.6)
  Smoking (10,649)                                                
  Never smoked                                                    2468 (23.2)
  Ex-smoker                                                       6153 (57.8)
  Active smoker                                                   2028 (19.0)
  FEV~1~[\*](#tfn1-copd-3-701){ref-type="table-fn"} (9963)        57.4 ± 13.4
  COPD severity (9963)                                            
  Mild                                                            3634 (35.5)
  Moderate                                                        5471 (53.4)
  Severe                                                          1146 (11.2)
  Comorbidities                                                   
  Hypertension (9876)                                             4706 (47.7)
  Diabetes (9453)                                                 1598 (16.9)
  Heart disease (9390)                                            1770 (18.8)
  Ulcer (9425)                                                    1637 (17.4)
  Depression (9333)                                               1196 (12.8)
  Anxiety (9397)                                                  2084 (19.5)
  Treatment                                                       
  Short-acting β~2~-adrenergic agonists (10,706)                  4165 (38.9)
  Long-acting β~2~-adrenergic agonists (10,610)                   1008 (9.5)
  Anticholinergics (10,615)                                       9002 (84.8)
  Theophyllines (10,703)                                          1263 (11.8)
  Inhaled corticoids (10,711)                                     2369 (22.1)
  Oral corticoids (10,711)                                        498 (4.6)
  Mucolytics (10,674)                                             950 (8.9)
  Oxygen therapy (10,007)                                         1351 (13.5)

**Notes:** Values expressed as mean ± standard deviation (minimum; maximum) or frequencies (percentages).

**Abbreviations:** COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in one second.

###### 

Health care resource utilization and disability days at work during the year previous to the study

  Health care resources and disability at work   N        Median   Mean   95% CI   
  ---------------------------------------------- -------- -------- ------ -------- ------
  Primary care physician visits (\#)             10,242   5        6.66   6.55     6.77
  Pneumologist visits (\#)                       9897     1        1.43   1.40     1.46
  Emergency room visits (\#)                     9574     1        1.60   1.54     1.65
  Hospital admissions (\#)                       8677     0        0.50   0.48     0.52
  Duration of stay (days)                        4744     5.6      7.24   6.91     7.57
  Duration of disability leave (days)            4984     5.1      8.86   8.21     9.52

**Abbreviation:** CI, confidence interval.

###### 

Health care resource utilization by age group

                                         N      Median   Mean    95% CI           p
  -------------------------------------- ------ -------- ------- ---------------- ---------
  Primary care physicians visits (\#):                                            
   -- 40--54 years                       921    4.00     5.73    (5.42--6.03)     
   -- 55--64 years                       2180   5.00     6.44    (6.20--6.68)     \<0.001
   -- 65--74 years                       3525   5.00     6.84    (6.64--7.02)     
   -- \>75 years                         1900   6.00     7.35    (7.06--7.63)     
  Pneumologist visits (\#):                                                       
   -- 40--54 years                       887    1.00     1.28    (1.18--1.36)     
   -- 55--64 years                       2106   1.00     1.39    (1.33--1.46)     \<0.001
   -- 65--74 years                       3418   1.00     1.45    (1.41--1.50)     
   -- \>75 years                         1840   1.00     1.57    (1.48--1.65)     
  Emergency room visits (\#):                                                     
   -- 40--54 years                       865    1.00     1.37    (1.20--1.54)     
   -- 55--64 years                       2039   1.00     1.59    (1.47--1.71)     \<0.001
   -- 65--74 years                       3311   1.00     1.62    (1.53--1.71)     
   -- \>75 years                         1783   1.00     1.79    (1.65--1.93)     
  Hospital admissions (\#):                                                       
   -- 40--54 years                       769    0.00     0.30    (0.24--0.36)     
   -- 55--64 years                       1828   0.00     0.40    (0.36--0.44)     \<0.001
   -- 65--74 years                       3007   0.00     0.52    (0.47--0.57)     
   -- \>75 years                         1670   0.00     0.68    (0.62--0.74)     
  Duration of disability leave (days):                                            
   -- 40--54 years                       693    8.00     15.60   (13.40--17.81)   
   -- 55--64 years                       1391   7.00     16.44   (14.73--18.14)   \<0.001
   -- 65--74 years                       1402   0.34     2.10    (1.62--2.58)     
   -- \>75 years                         677    0.00     0.42    (0.22--0.62)     

**Abbreviation:** CI, confidence interval.

###### 

Health care resource utilization by COPD severity

                                         N      Median   Mean    95% CI          P
  -------------------------------------- ------ -------- ------- --------------- ---------
  Primary care physician visits (\#):                                            
   -- Mild COPD                          3529   4.00     5.15    (5.00--5.30)    
   -- Moderate COPD                      5246   6.00     7.08    (6.92--7.25)    \<0.001
   -- Severe COPD                        1096   7.50     9.54    (9.09--9.99)    
  Pneumologist visits (\#):                                                      
   -- Mild COPD                          3369   1.00     1.01    (0.97--1.04)    
   -- Moderate COPD                      5090   1.00     1.52    (1.48--1.56)    \<0.001
   -- Severe COPD                        1084   2.00     2.32    (2.19--2.46)    
  Emergency room visits (\#):                                                    
   -- Mild COPD                          3255   0.00     1.01    (0.94--1.08)    
   -- Moderate COPD                      4623   1.00     1.71    (1.63--1.79)    \<0.001
   -- Severe COPD                        1057   2.00     2.88    (2.68--3.08)    
  Hospital admissions (\#):                                                      
   -- Mild COPD                          2975   0.00     0.24    (0.20--0.28)    
   -- Moderate COPD                      4406   0.00     0.50    (0.47--0.52)    \<0.001
   -- Severe COPD                        1001   1.00     1.33    (1.22--1.44)    
  Duration of disability leave (days):                                           
   -- Mild COPD                          1967   4.38     7.22    (6.39--8.05)    
   -- Moderate COPD                      2495   5.69     9.75    (8.77--10.73)   \<0.001
   -- Severe COPD                        348    4.48     11.02   (7.27--14.77)   

**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease.

###### 

Comparison of different component of total costs by gender

                                       Gender   N      Mean                                                 Median    95% CI
  ------------------------------------ -------- ------ ---------------------------------------------------- --------- --------------------
  Cost of hospitalization              Men      8030   828.28[\*](#tfn6-copd-3-701){ref-type="table-fn"}    563.75    (788.75--867.81)
                                       Women    2590   673.62                                               430.28    (610.77--736.47)
  Cost of drugs per year               Men      8030   500.30[\*](#tfn6-copd-3-701){ref-type="table-fn"}    529.25    (491.24--509.36)
                                       Women    2590   467.13                                               365.00    (451.60--482.67)
  Cost of visits to emergency rooms    Men      8030   136.80[\*](#tfn6-copd-3-701){ref-type="table-fn"}    104.52    (132.49--141.11)
                                       Women    2590   126.59                                               104.52    (119.30--133.88)
  Cost of diagnostic tests             Men      8030   131.88[\*](#tfn6-copd-3-701){ref-type="table-fn"}    97.32     (128.61--135.16)
                                       Women    2590   120.35                                               97.32     (114.89--125.81)
  Cost of visits to primary care       Men      8030   107.69                                               83.85     (105.57--109.81)
                                       Women    2590   104.37                                               83.85     (100.72--108.01)
  Cost of oxygen therapy per year      Men      8030   101.87[\*](#tfn6-copd-3-701){ref-type="table-fn"}    50.72     (95.17--108.59)
                                       Women    2590   68.20                                                15.41     (58.32--78.09)
  Cost of visits to pneumologists      Men      8030   95.58[\*](#tfn6-copd-3-701){ref-type="table-fn"}     70.53     (93.21--97.95)
                                       Women    2590   87.22                                                70.53     (83.26--91.18)
  Cost of disability leave             Men      8030   69.02                                                21.90     (62.67--75.38)
                                       Women    2590   60.18                                                19.22     (50.33--70.03)
  Cost of pneumococcal vaccine         Men      8030   4.65                                                 4.36      (4.50--4.80)
                                       Women    2590   4.38                                                 4.05      (4.12--4.64)
  Cost of influenza vaccine            Men      8030   0.20[\*](#tfn6-copd-3-701){ref-type="table-fn"}      0.00      (0.18--0.21)
                                       Women    2590   0.23                                                 0.00      (0.21--0.25)
  Total annual cost per COPD patient   Men      8030   1989.20[\*](#tfn6-copd-3-701){ref-type="table-fn"}   1112.20   (1937.48--2040.93)
                                       Women    2590   1724.53                                              984.23    (1643.35--1805.71)

**Note:** p \< 0.05 between sexes, differences between means not significant when not stated.

**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease.

###### 

Comparison of different component of costs by tobacco use

                                       Tobacco user   N      Mean                                                 Median    95% CI
  ------------------------------------ -------------- ------ ---------------------------------------------------- --------- --------------------
  Cost of hospitalization              No             2468   654.79                                               419.15    (592.56--717.03)
                                       Yes            8181   827.73[\*](#tfn8-copd-3-701){ref-type="table-fn"}    561.51    (788.39--867.06)
  Cost of drugs per year               No             2468   476.91                                               529.25    (460.85--492.98)
                                       Yes            8181   497.00[\*](#tfn8-copd-3-701){ref-type="table-fn"}    529.25    (488.05--505.95)
  Cost of visits to emergency rooms    No             2468   119.42                                               52.26     (112.51--126.34)
                                       Yes            8181   138.69[\*](#tfn8-copd-3-701){ref-type="table-fn"}    104.52    (134.34--143.04)
  Cost of diagnostic tests             No             2468   120.30                                               97.32     (114.81--125.80)
                                       Yes            8181   131.54[\*](#tfn8-copd-3-701){ref-type="table-fn"}    97.32     (128.29--134.79)
  Cost of visits to primary care       No             2468   104.37                                               83.85     (100.55--108.18)
                                       Yes            8181   107.79[\*](#tfn8-copd-3-701){ref-type="table-fn"}    83.85     (105.70--109.88)
  Cost of oxygen therapy per year      No             2468   71.04                                                18.67     (60.79--81.28)
                                       Yes            8181   100.260[\*](#tfn8-copd-3-701){ref-type="table-fn"}   48.87     (93.64--106.87)
  Cost of visits to pneumology         No             2468   87.19                                                70.53     (83.21--91.17)
                                       Yes            8181   95.33[\*](#tfn8-copd-3-701){ref-type="table-fn"}     70.53     (92.97--97.68)
  Cost of disability leave             No             2468   41.07                                                6.04      (32.08--50.06)
                                       Yes            8181   74.48[\*](#tfn8-copd-3-701){ref-type="table-fn"}     26.36     (68.06--80.89)
  Cost of pneumococcal vaccine         No             2468   4.96                                                 4.69      (4.68--5.23)
                                       Yes            8181   4.48[\*](#tfn8-copd-3-701){ref-type="table-fn"}      4.17      (4.34--4.63)
  Cost of influenza vaccine            No             2468   0.17                                                 0.09      (0.15--0.19)
                                       Yes            8181   0.22[\*](#tfn8-copd-3-701){ref-type="table-fn"}      0.14      (0.21--0.23)
  Total annual cost per COPD patient   No             2468   1693.64                                              966.82    (1611.71--1775.57)
                                       Yes            8181   1990.09[\*](#tfn8-copd-3-701){ref-type="table-fn"}   1113.66   (1938.84--2041.33)

**Notes:** p\<0.05 between tobacco users, differences between means not significant when not stated. Tobacco use: "Yes" includes current smokers and ex-smokers, "No" includes never smoked.

**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease.

###### 

Comparison of different costs by hospitalization

                                       Hospital admission   N      Mean                                                  Median    95% CI
  ------------------------------------ -------------------- ------ ----------------------------------------------------- --------- --------------------
  Cost of hospitalization              No                   6015   0.00                                                  0.00      (0.00--0.00)
                                       Yes                  2662   3173.56[\*](#tfn10-copd-3-701){ref-type="table-fn"}   2010.00   (3088.66--3258.46)
  Cost of drugs per year               No                   6015   465.71                                                365.00    (455.80--475.61)
                                       Yes                  2662   610.10[\*](#tfn10-copd-3-701){ref-type="table-fn"}    529.25    (593.16--627.03)
  Cost of visits to emergency rooms    No                   6015   80.69                                                 60.48     (77.16--84.22)
                                       Yes                  2662   291.49[\*](#tfn10-copd-3-701){ref-type="table-fn"}    209.04    (282.24--300.74)
  Cost of diagnostic tests             No                   6015   98.87                                                 97.32     (96.09--101.64)
                                       Yes                  2662   224.17[\*](#tfn10-copd-3-701){ref-type="table-fn"}    194.64    (216.69--231.66)
  Cost of visits to primary care       No                   6015   91.86                                                 67.08     (89.84--93.88)
                                       Yes                  2662   158.70[\*](#tfn10-copd-3-701){ref-type="table-fn"}    134.16    (154.17--163.23)
  Cost of oxygen therapy per year      No                   6015   36.45                                                 0.00      (31.68--41.21)
                                       Yes                  2662   261.56[\*](#tfn10-copd-3-701){ref-type="table-fn"}    221.80    (244.47--278.65)
  Cost of visits to pneumologists      No                   6015   71.65                                                 70.53     (69.64--73.66)
                                       Yes                  2662   162.46[\*](#tfn10-copd-3-701){ref-type="table-fn"}    141.06    (157.04--167.88)
  Cost of disability leave             No                   6015   49.84                                                 16.30     (44.41--55.27)
                                       Yes                  2662   105.47[\*](#tfn10-copd-3-701){ref-type="table-fn"}    37.75     (90.65--120.28)
  Cost of pneumococcal vaccine         No                   6015   4.23                                                  3.89      (4.07--4.40)
                                       Yes                  2662   5.84[\*](#tfn10-copd-3-701){ref-type="table-fn"}      5.67      (5.56--6.11)
  Cost of influenza vaccine            No                   6015   0.22                                                  0.00      (0.21--0.24)
                                       Yes                  2662   0.16[\*](#tfn10-copd-3-701){ref-type="table-fn"}      0.00      (0.14--0.18)
  Total annual cost per COPD patient   No                   6015   911.90                                                816.23    (895.86--927.95)
                                       Yes                  2662   5007.99[\*](#tfn10-copd-3-701){ref-type="table-fn"}   4099.66   (4099.66--5111.82)

**Note:** p \< 0.05 between hospital admitted patients, differences between means not significant when not stated.

**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease.

###### 

Linear regression model to evaluate ability of variables to predict total costs

  Variable                          B        Standard error   T      Significance   95% CI   
  --------------------------------- -------- ---------------- ------ -------------- -------- --------
  Heart disease                     227.9    72.4             −3.1   0.002          85.8     369.9
  Physical component (SF-12)        −8.9     3.0              −2.9   0.003          −14.8    −3.0
  FEV~1~                            −10.6    2.2              −4.8   0.000          −14.9    −6.3
  No of visits to primary care      22.8     5.2              4.3    0.000          12.6     33.0
  No of visits to pneumology        216.5    21.5             10.0   0.000          174.3    258.8
  No of visits to emergency rooms   180.5    14.4             12.4   0.000          152.1    209.0
  No of hospital admissions         1143.1   33.8             33.7   0.000          1076.6   1209.6
  Duration of stay in days          50.0     3.4              14.4   0.000          43.2     56.8
  Duration of disability leave      16.9     0.9              17.3   0.000          15.0     18.9

**Abbreviations:** CI, confidence interval; COPD, chronic obstructive pulmonary disease; FEV~1~, forced expiratory volume in one second; SF-12, short form 12-item quality of life questionnaire.
